Loading…
Ionis Pharmaceuticals, Inc. is projected to rise to $65.08 by 2027, a +22% move from its current price of $53.28. IONS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $52.13 | $53.31 | $54.51 | +0.05% |
| Aug 2 | $51.67 | $53.33 | $55.05 | +0.10% |
| Aug 3 | $51.33 | $53.36 | $55.47 | +0.15% |
| Aug 4 | $51.05 | $53.39 | $55.83 | +0.20% |
| Aug 5 | $50.80 | $53.41 | $56.15 | +0.25% |
| Aug 6 | $50.59 | $53.44 | $56.45 | +0.30% |
| Aug 7 | $50.39 | $53.46 | $56.73 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $50.39 | $53.46 | $56.73 | +0.35% |
| Week 2 | $49.34 | $53.65 | $58.34 | +0.69% |
| Week 3 | $48.59 | $53.84 | $59.65 | +1.04% |
| Week 4 | $47.99 | $54.02 | $60.82 | +1.39% |
| Week 5 | $47.48 | $54.21 | $61.89 | +1.74% |
| Week 6 | $47.05 | $54.40 | $62.89 | +2.10% |
| Week 7 | $46.67 | $54.58 | $63.85 | +2.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company that provides RNA-targeted medicines in the United States. Its portfolio includes TRYNGOLZA to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines.
It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Ionis Pharmaceuticals, Inc. (IONS) is a healthcare stock. The stock's current price is $52.95 and the market cap is $8.75B. It ranks 929. The 30-day price range is $44.54 to $62.95, RSI14 is 20, and the sentiment is NEUTRAL.
The SMA50 is $73.18 and the SMA200 is $75.83, with near-term support at $52.95 and resistance at $86.33. The long-range forecast shows a bullish trajectory, with 2030 avg $97.13 (min $72.51, max $140.08) and ROI 83.4; 2040 avg $173.03 (min $112.04, max $288.70) and ROI 226.8; and 2050 avg $408.47 (min $237.16, max $744.02) and ROI 671.4.
A major floor 42.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.6% away) — a key level to hold.
The nearest ceiling, 62.0% above — a clean break opens room to run.
A major ceiling 83.1% above — clearing it would confirm fresh momentum.
Key IONS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IONS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $55.03 | Sell | $54.45 | Sell |
| MA 10 | $54.57 | Sell | $55.83 | Sell |
| MA 20 | $61.25 | Sell | $59.92 | Sell |
| MA 50 | $69.89 | Sell | $66.80 | Sell |
| MA 100 | $72.05 | Sell | $70.41 | Sell |
| MA 200 | $75.26 | Sell | $69.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.24 | Buy |
| Stoch RSI (14) | 55.64 | Neutral |
| CCI (20) | -56.70 | Neutral |
| Williams %R (14) | -91.32 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -3.00 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 8.68 | Buy |
| TRIX (15) | -1.11 | Sell |
| Awesome (5,34) | -12.47 | Sell |
| Ultimate (7,14,28) | 41.04 | Neutral |
| Momentum (10) | -1.37 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 54.59 | Sell |
| ADX (14) | 37.53 | Sell |
| ATR (14) | 1.58 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 20, and the stock is trading below both the SMA50 and the SMA200, which are $73.18 and $75.83 respectively. Support is at $52.95 and resistance at $86.33. The 30-day range runs from $44.54 to $62.95.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $52.95 | $53.28 | $72.54 | 0% | Neutral | |
| $52.75 | $65.08 | $84.34 | +22% | Bullish | |
| $61.42 | $77.52 | $103.69 | +46% | Bullish | |
| $69.17 | $88.94 | $121.95 | +67% | Bullish | |
| $75.87 | $99.17 | $138.83 | +86% | Bullish | |
| $78.04 | $103.54 | $147.61 | +94% | Bullish | |
| $78.55 | $105.65 | $153.11 | +98% | Bullish | |
| $85.40 | $116.35 | $171.13 | +118% | Bullish | |
| $92.46 | $127.50 | $190.13 | +139% | Bullish | |
| $107.43 | $149.88 | $226.36 | +181% | Bullish | |
| $126.98 | $186.63 | $297.36 | +250% | Bullish | |
| $268.02 | $430.01 | $741.30 | +707% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $52.95 | $53.28 | $62.06 | +0.00% |
| August 2026 | $46.22 | $54.04 | $64.50 | +1.42% |
| September 2026 | $47.34 | $55.73 | $67.27 | +3.14% |
| October 2026 | $47.21 | $55.88 | $68.04 | +0.27% |
| November 2026 | $47.41 | $56.37 | $69.12 | +0.87% |
| December 2026 | $49.24 | $58.78 | $72.54 | +4.28% |
Click any year to see its month-by-month IONS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IONS price prediction for 2026 points to an average of $53.28 (low $52.95, high $72.54) — a potential gain of 0% on today's $53.28. Price action looks broadly range-bound.
In 2027, IONS is projected to trade between $52.75 and $84.34, averaging $65.08 — a potential gain of +22% from today's $53.28. That is up +22% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Ionis Pharmaceuticals, Inc.'s 2028 outlook centres on $77.52, within a $61.42 to $103.69 range. That is up +19% on the projected 2027 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2029, IONS could reach as high as $121.95, with a base case around $88.94 and support toward $69.17 — roughly +67% from $53.28. Buyers look set to stay in control over this stretch.
Expect IONS to range from $75.87 to $138.83 through 2030. The $99.17 average target implies a +86% move from current prices. That is up +11% on the projected 2029 average. Momentum favours further upside here.
The IONS price prediction for 2031 points to an average of $103.54 (low $78.04, high $147.61) — a potential gain of +94% on today's $53.28. Buyers look set to stay in control over this stretch.
In 2032, IONS is projected to trade between $78.55 and $153.11, averaging $105.65 — a potential gain of +98% from today's $53.28. That is up +2% on the projected 2031 average. Momentum favours further upside here.
Ionis Pharmaceuticals, Inc.'s 2033 outlook centres on $116.35, within a $85.40 to $171.13 range. That is up +10% on the projected 2032 average. That marks a +118% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IONS could reach as high as $190.13, with a base case around $127.50 and support toward $92.46 — roughly +139% from $53.28. Momentum favours further upside here.
Expect IONS to range from $107.43 to $226.36 through 2035. The $149.88 average target implies a +181% move from current prices. That is up +18% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IONS price prediction for 2040 points to an average of $186.63 (low $126.98, high $297.36) — a potential gain of +250% on today's $53.28. Momentum favours further upside here.
In 2050, IONS is projected to trade between $268.02 and $741.30, averaging $430.01 — a potential gain of +707% from today's $53.28. That is up +130% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IONS today (≈ 18.768769 IONS) could be worth
$8,070.78
+$7,070.78 (+707%) by 2050 · US Dollar
Based on the average projected IONS price of $430.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IONSwould be worth at today's price.
$1,000 invested in IONS on Jul 30, 2025 (≈ 23.057414 IONS) would be worth
$1,228.5
+$228.5 (+22.8%) today · 1.23× · US Dollar
Based on a IONS entry price of $43.37 vs. today's $53.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $55.87 | $953.64 | -4.6% |
| 1 month ago | $79.29 | $671.96 | -32.8% |
| 3 months ago | $75.28 | $707.76 | -29.2% |
| 6 months ago | $82.67 | $644.49 | -35.6% |
| 1 year ago | $43.37 | $1,228.5 | +22.8% |
| All time (5.0y) ago | $37.63 | $1,415.89 | +41.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IONS forecast.
Our base-case forecast reaches $110.00 around 2033.
Implied market cap at $110.00: $18.28B
The multi-year forecast shows a bullish trajectory with sentiment turning BULLISH from 2028 onward. The forecast cites a rising average from 2028 to 2050, with 2030 avg $97.13, 2040 avg $173.03 and 2050 avg $408.47. Notably, the 2030, 2040 and 2050 min and max values are $72.51/$140.08, $112.04/$288.70, and $237.16/$744.02 respectively, with ROIs of 83.4, 226.8 and 671.4.
These are estimates, not guarantees, and actual results may differ due to market conditions and other factors.
Tap a question to reveal the answer.
The 2030 forecast shows min $72.51, avg $97.13, max $140.08; ROI 83.4; sentiment BULLISH.
The forecast suggests a bullish path from 2028 onward, with 2030 avg $97.13, 2040 avg $173.03 and 2050 avg $408.47; ROIs 83.4, 226.8 and 671.4; early years show neutral sentiment. These are estimates, not guarantees.
Yes, the 2030 max price is $140.08 and the avg is $97.13, indicating $100 could be exceeded in 2030.
Current price is $52.95; Market cap is $8.75B.
The 30-day range is $44.54 to $62.95.
Ionis Pharmaceuticals, Inc. Community Discussion
0Share your Ionis Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.